News
QUANTUM GENOMICS : Recrutement aux Etats-Unis des premiers patients de l'étude NEW-HOPE dans l'hypertension artérielle
Communiqué de presse
Paris, le 15 novembre 2017
Une étude menée aux Etats-Unis pour un meilleur ciblage
NEW-HOPE : un essai clinique de phase II récompensé par le prix Galien....
Unternehmensanalyse Gilead Sciences
Gilead Sciences ist ein sehr profitables Unternehmen aus der Pharma- und Biotechnik Branche. Das Unternehmen produziert dabei Medikamente und Präparate für diverse Krankheiten. Die wichtigsten....
Is Valeant Turning Things Around?
Valeant Pharmaceuticals (NYSE: VRX) is notorious for its drug price gouging scandal a few years ago, an incident that caused the stock to tank and public opinion of the company plummeting to hit....
Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks
Donald Trump's next top pick for running the Department of Health and Human Services (HHS) is Eli Lilly & Co. (NYSE: LLY) executive Alex Azar, and that's drawing the ire of patient advocates....
Medicrea participera à la conférence annuelle Piper Jaffray Healthcare
Medicrea participera à la 29ème conférence annuelle de Piper Jaffray Healthcare à New York
Lyon et New York, 14 novembre, 2017 - Le Groupe Medicrea (Euronext Growth Paris : FR0004178572 -....
Ionis Pharmaceuticals Inc. Sets Itself Up for Growth
Ionis Pharmaceuticals' (NASDAQ: IONS) third-quarter earnings were a bit humdrum considering partner Biogen (NASDAQ: BIIB) spilled the beans on sales of Spinraza a few weeks ago when it reported....
Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer
Bayer AG (NASDAQOTH: BAYRY) has entered into a collaborative partnership with Loxo Oncology (NASDAQ: LOXO) that could make it a global leader in cancer drugs that are used in patients based on....
Here's What's Behind Synergy Pharmaceuticals' 15.6% Drop Today
After pricing an equity offering that will dilute current investors but help shore up its balance sheet, shares in Synergy Pharmaceuticals (NASDAQ: SGYP) are tumbling 15.6% as of 1:45 p.m.....
Keryx Biopharma Down 17% Despite Drug Approval
Last week, Keryx Biopharmaceuticals (NASDAQ: KERX) fell a whopping 17% after missing analyst estimates for its key drug, Auryxia, which is used to control phosphorus levels in patients with....
BASTIDE : Bonne dynamique au 1er trimestre 2017-2018 Chiffre d'affaires : + 22%
En K€ - 1er trimestre
2016-2017
2017-2018
Variation
Chiffre d'affaires
50 738
61 765
+ 21,7%
Le Groupe Bastide réalise un début d'exercice très solide avec un....
5 Supernova Stocks That Have Flown Under the Radar
Recently on the Rule Breakers Investing podcast, Motley Fool co-founder David Gardner reviewed the performance of two sets of his buy-and-hold stock picks: one set with a five-year horizon, and....
3 Top Big Pharma Dividend Stocks You Can Buy Right Now
Big pharma stocks have long been favorites for dividend-seeking investors, and for good reason. Major pharmaceutical companies typically generate strong cash flow, which allows them to pay high....
What Investors Need to Know About Investing in Low PE Stocks
What do Warren Buffett, Ben Graham, Seth Klarman, and Peter Lynch all have in common? Besides being wildly successful investors, they're all are adherents to value investing, a method where one....
Why Sears Holdings, Immunomedics, and J.C. Penney Slumped Today
Monday was a good day for the stock market, with major benchmarks finishing with modest gains to sustain the generally bullish sentiment among investors. Some investors remain uncertain about....
Why Roku, GGP, and Nektar Therapeutics Jumped Today
The stock market got off to a solid start on Monday, bouncing back from small losses early in the trading day to finish with modest gains. Major benchmarks were up less than a quarter percent as....
Why Nektar Therapeutics Shares Are Rallying 13.8% Today
After the company presented results from an early-stage study of its NKTR-214 in solid tumor cancer at the 2017 Society for Immunotherapy of Cancer (SITC) annual meeting, Nektar Therapeutics....
Qiagen NV Meets Its Own 3rd-Quarter Expectations
Qiagen (NASDAQ: QGEN) reported third-quarter earnings in line with its revenue and earnings guidance, which disappointed investors who have come to expect earnings beats.MetricQ3 2017Continue....
MEDICREA - Mise à disposition du Document de référence 2016
Medicrea met à disposition son Document de référence 2016
Lyon et New York, le 13 novembre 2017 – Le Groupe Medicrea (Euronext Growth Paris : FR0004178572 - ALMED), pionnier de la convergence....
Jounce Therapeutics, Inc. (JNCE) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Jounce Therapeutics, Inc. (NASDAQ: JNCE) Q3 2017 Earnings Conference CallNov. 13, 2017 8:00 a.m. ETOperatorContinue readingSource: Fool.com
Will Invitae Ever Turn a Profit?
Genetic-testing leader Invitae (NYSE: NVTA) has promised to usher in a new age of healthcare, one influenced by every individual's unique genetic profile. To do so, it's ditching the industry's....
A Rare Quarterly Appearance by bluebird bio Inc.'s Management
bluebird bio (NASDAQ: BLUE) released third-quarter earnings complete with a conference call, which the biotech doesn't usually hold for quarterly results, but this quarter was different with....
3 Top Healthcare Stocks to Buy in November
At 14.1%, healthcare is the third largest weighted sector in the S&P 500 index, and with 76 million baby boomers getting older and living longer, owning healthcare stocks in your portfolio....
Is Exact Sciences Corporation Stock a Buy?
Owning a stock that doubles in value in less than 11 months is exciting. But what word do you use for a stock that rises to 4.5 times its original price in that amount of time? Thrilling?....
Can Marijuana Cure Alzheimer's Disease?
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of Aβ amyloid plaques and twisted tangles of a protein called "tau" in regions of the brain responsible for....
Evotec: Nur eine Korrektur oder droht Schlimmeres?
Irgendwann trifft es auch die beste Aktie. In der letzten Handelswoche war nun Evotec an der Reihe. Nach einer monatelangen Rally ab Februar 2016 im Zuge derer der Kurs Bitcoin-artig um fast 700 %....
